In today’s Pharmaceutical Executive Daily, we cover the emergence of TrumpRx and its implications for direct-to-consumer drug ...

Britain's medicines regulator said on Friday it had made the world's largest seizure of unlicensed weight-loss medicines, ...

Sure, Eli Lilly’s Tirzepatide-based drugs have caught up significantly to Novo Nordisk’s semaglutide-based ones. As a result, ...

"UK regulators seize illegal weight loss drugs amid global pricing shake-up" was originally created and published by ...

Eli Lilly said on Friday it would acquire gene therapy developer Adverum Biotechnologies in a deal valued at up to $261.7 ...

"Lilly and Incyte to seek approval of alopecia JAK inhibitor in children" was originally created and published by Clinical ...

Eli Lilly announced on Friday safety and efficacy results from two separate late-stage studies testing its approved drugs for ...

Sometimes the biggest moments at a conference happen backstage. At the annual STAT Summit, that kind of moment involved a ...

See, LLY stock warrants your attention. Why? Because it offers monopoly-like high margins at a discounted price.

Just as Adverum’s cash reserves were running dry, Eli Lilly has swooped in to buy the biotech and its phase 3-stage eye disease gene therapy.

Eli Lilly said on Friday it would acquire gene therapy developer Adverum Biotechnologies in a deal valued at up to $261.7 ...